Experimental cell therapy takes on deadliest brain cancer
NCT ID NCT07384390
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new cell therapy called TH-CART-027 in 21 adults with recurrent grade 4 glioma, a very aggressive brain cancer. The therapy is given directly into the tumor or brain fluid. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TH-CART-027 (a type of CAR-T cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for recurrent grade 4 glioma, a very aggressive brain cancer.
What could go wrong
This is a very early, small trial (21 people) focused on safety. The therapy may not shrink tumors or improve survival, and there are risks like brain inflammation or other severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R GRADE 4 GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••